Sequential toripalimab and paclitaxel for head and neck cancer with poor performance status
Treatments studied
Part of Cancer clinical trials.
This trial tests a sequence of two drugs, toripalimab (an immunotherapy that helps your immune system fight cancer) and paclitaxel (a chemotherapy drug), for people with head and neck cancer that has spread or cannot be cured. It is designed for patients who have a lower level of physical function (ECOG score of 2) and aims to see if this treatment can help them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have head and neck cancer that has spread or cannot be cured, and it must be measurable on scans.
- You must be 18 years or older and expected to live at least 6 more months.
- You must have a performance status of 2, meaning you are up and about more than half the day but may need some rest.
- Your liver and blood counts must be within certain limits (bilirubin ≤ 3 times normal, hemoglobin > 8, and absolute neutrophil count > 1.0).
- You cannot have untreated brain metastases, uncontrolled COPD, heart disease, or autoimmune disease, and you cannot be on other investigational drugs.
- You must not be taking more than 10 mg of prednisone (or equivalent steroid) daily before starting, and you must avoid pregnancy or sperm donation during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This study tests whether adding an immunotherapy drug (toripalimab) to chemotherapy before surgery can help shrink tumors and improve outcomes for patients with locally advanced head and neck cancer. It aims to see if this combination is better than surgery alone or surgery with chemotherapy.
This trial tests whether continuing treatment with an immunotherapy drug called toripalimab after standard treatment helps prevent head and neck cancer from coming back. It's for patients with high-risk features who have no remaining cancer after their first treatment.
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
This trial tests a combination of drugs before surgery for head and neck cancer. It aims to shrink tumors and improve outcomes, and the study compares adding another targeted drug to the standard combination.
Hear when a new Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.